LOS ANGELES--(BUSINESS WIRE)--Abraxis BioScience, Inc. (NASDAQ:ABBI), an integrated, global biopharmaceutical company, today reported unaudited financial results for the first quarter ended March 31, 2007.
First quarter 2007 revenue increased 47 percent to $212.2 million, versus $144.5 million in the first quarter of 2006. Revenue for company-wide, hospital-based products in the first quarter of 2007 was $140.5 million, which included the acquired anesthetic/analgesic products, a 24 percent increase from the prior year quarter. For the quarter, ABRAXANE® (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) revenue increased 134 percent to $70.9 million, which included deferred revenue of $9.1 million, versus $30.3 million in the prior year period.
